INVO Fertility (IVF) lifts Q2 revenue 17% as clinics turn profitable

Rhea-AI Filing Summary

INVO Fertility, Inc. reported stronger results for the quarter ended June 30, 2026, with revenue of $2,175,485, up 17% from $1,863,654 a year earlier, driven primarily by the February 2026 acquisition of Family Beginnings and growth across its clinic network. Clinic revenue rose 18% to $2,167,785. Cost of services increased to $1,352,665 and selling, general and administrative expenses declined to $1,906,750, resulting in a narrower loss from operations of $1,289,650 versus $2,990,088 in Q2 2025.

Net income was $888,740, compared to a net loss of $3,618,969, reflecting a $2,452,032 gain on remeasurement related to the Birmingham clinic acquisition and the absence of prior-year discontinued-operation losses from NAYA Therapeutics. Company-wide Adjusted EBITDA was $(1,032,660), a deeper loss than $(587,229) a year earlier, while the clinic platform generated Clinic-Level Adjusted EBITDA of $333,026, up from $163,945 in Q1 2026. Cash increased to $3.7 million at June 30, 2026, from $2.1 million at December 31, 2025, and the company reported 2,506,969 common shares outstanding as of August 14, 2026.

Positive

• Revenue grew 17% year over year to $2.18 million, with clinic revenue up 18%, indicating expanding fertility clinic activity and successful integration of the Family Beginnings acquisition.
• Net income improved to $0.9 million from a $3.6 million loss, aided by a $2.45 million gain on Birmingham remeasurement and elimination of large discontinued-operation losses.
• Clinic-Level Adjusted EBITDA rose to $333,026 in Q2 2026 from $163,945 in Q1 2026, showing improved profitability at the clinic-platform level before corporate costs.
• Cash increased to $3.7 million at June 30, 2026 from $2.1 million at year-end 2025, strengthening the company’s liquidity position.

Negative

• Adjusted EBITDA loss widened to $(1.03) million from $(0.59) million year over year, indicating higher consolidated-level losses after corporate expenses.
• Loss from operations, while improved, remained $(1.29) million in Q2 2026, showing the business is not yet profitable on an operating basis.
• Six-month net loss from continuing operations was $4.65 million, reflecting ongoing negative earnings despite the one-time remeasurement gain in the quarter.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Total Revenue Q2 2026: $2,175,485 Clinic Revenue Q2 2026: $2,167,785 Net Income Q2 2026: $888,740 +5 more

8 metrics

Total Revenue Q2 2026 $2,175,485 Revenue for the three months ended June 30, 2026; up 17% from $1,863,654 in Q2 2025

Clinic Revenue Q2 2026 $2,167,785 Clinic revenue for Q2 2026; increased 18% from $1,832,094 in Q2 2025

Net Income Q2 2026 $888,740 Net income for the three months ended June 30, 2026, versus net loss of $3,618,969 in Q2 2025

Loss from Operations Q2 2026 $(1,289,650) Loss from operations for Q2 2026, improved from $(2,990,088) in Q2 2025

Adjusted EBITDA Q2 2026 $(1,032,660) Adjusted EBITDA for Q2 2026 versus $(587,229) in Q2 2025

Clinic-Level Adjusted EBITDA Q2 2026 $333,026 Fertility Clinic Services Segment EBITDA in Q2 2026; up from $163,945 in Q1 2026

Cash Balance $3,700,000 Approximate cash at June 30, 2026; up from approximately $2,100,000 at December 31, 2025

Gain on Remeasurement $2,452,032 Gain on remeasurement related to the Birmingham acquisition in Q2 2026

Key Terms

Adjusted EBITDA, Clinic-Level Adjusted EBITDA, gain on remeasurement, loss from discontinued operations, +1 more

5 terms

Adjusted EBITDA financial

"Included in this press release are references to Adjusted EBITDA and Clinic-Level Adjusted EBITDA"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

Clinic-Level Adjusted EBITDA financial

"Clinic-Level Adjusted EBITDA represents Adjusted EBITDA generated by the Company’s fertility clinic operations"

Clinic-level adjusted EBITDA measures a single clinic’s core operating profit before interest, taxes, depreciation and amortization, with additional one-off, non-cash or non-operational items removed so the number reflects recurring cash earnings from running that clinic. Think of it as the clinic’s day-to-day cash profit after stripping out accounting entries and unusual events; investors use it to compare profitability across clinics and assess underlying business performance independent of financing or tax differences.

gain on remeasurement financial

"The Company recognized an approximate gain of $2.5 million on remeasurement related to the Birmingham acquisition"

loss from discontinued operations financial

"The prior-year period included approximately $2.1 million of losses from discontinued operations related to NAYA Therapeutics"

intravaginal culture medical

"our clinics offer a variety of fertility services including in vitro fertilization and the intravaginal culture procedure"

A fertility technique in which eggs and sperm are placed together inside a small, sealed device that is inserted into the woman’s vagina so fertilization and initial embryo development occur using body heat instead of a full laboratory incubator. For investors, it matters because it can lower clinic costs, broaden access to assisted reproduction, and shift demand toward smaller medical devices and different regulatory and reimbursement pathways—similar to moving part of a factory process back into the customer's hands.

Earnings Snapshot

Revenue: $2,175,485 vs. $1,863,654

Quarter ended June 30, 2026

Revenue $2,175,485 vs. $1,863,654 Up 17% year over year

Net income (loss) $888,740 vs. $(3,618,969) Swing to profit from prior-year loss

Adjusted EBITDA $(1,032,660) vs. $(587,229) Loss widened versus prior year

FAQ

How did INVO Fertility (IVF) perform financially in Q2 2026?

INVO Fertility reported Q2 2026 revenue of $2.18 million, up 17% from Q2 2025, and net income of $888,740 versus a $3.62 million loss a year earlier, helped by a $2.45 million gain on the Birmingham acquisition remeasurement.

What drove revenue growth for INVO Fertility (IVF) in Q2 2026?

Revenue grew 17% to $2,175,485, primarily due to the February 2026 acquisition of Family Beginnings and organic growth at Wisconsin Fertility Institute and the Georgia clinic, which lifted clinic revenue by 18% year over year.

Is INVO Fertility’s clinic platform profitable in Q2 2026?

Yes. The clinic platform generated Clinic-Level Adjusted EBITDA of $333,026 in Q2 2026, up from $163,945 in Q1 2026. This measure reflects fertility clinic operations before corporate operating and public company expenses, highlighting underlying clinic-level earnings capacity.

What was INVO Fertility’s Adjusted EBITDA in Q2 2026?

INVO Fertility reported Adjusted EBITDA of $(1,032,660) in Q2 2026, compared to $(587,229) in Q2 2025. The wider Adjusted EBITDA loss reflects corporate-level expenses and adjustments, despite improved revenue and clinic-level profitability.

What is INVO Fertility’s cash position and share count as of mid-2026?

INVO Fertility held $3.7 million in cash at June 30, 2026, up from $2.1 million at December 31, 2025. As of August 14, 2026, the company had 2,506,969 shares of common stock outstanding.

How did INVO Fertility’s operating loss change year over year in Q2 2026?

The loss from operations improved to $(1,289,650) in Q2 2026 from $(2,990,088) in Q2 2025. This reflects higher revenue and lower selling, general and administrative expenses, partially offset by increased cost of services.

What was the impact of the Birmingham acquisition on INVO Fertility’s Q2 2026 results?

INVO Fertility recorded a $2,452,032 gain on remeasurement related to acquiring the remaining ownership interests in its Birmingham clinic. This non-cash gain significantly contributed to the $888,740 net income reported for Q2 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/17/2026 - 08:36 AM Accepted by SEC EDGAR 08/17/2026 - 08:35 AM Learn about SEC filing dates

false 0001417926 0001417926 2026-08-17 2026-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 17, 2026

INVO FERTILITY, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-39701		20-4036208
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

5582 Broadcast Court

Sarasota, FL 34240

(Address of principal executive offices, including zip code)

(978) 878-9505

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		IVF		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 17, 2026, INVO Fertility, Inc. (the “Company”), issued a press release announcing financial results for the quarter ended June 30, 2026. The text of the press release is furnished as Exhibit 99.1 to this current report.

The information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated August 17, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document.)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 17, 2026	INVO FERTILITY, INC.
	/s/ Steven Shum
	Steven Shum
	Chief Executive Officer

-3-

Exhibit 99.1

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., August 17, 2026 — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared to Q2 2025 unless otherwise noted)

●	Revenue was $2,175,485, an increase of 17% compared to $1,863,654.
●	Consolidated clinic revenue increased 18% to $2,167,785, compared to $1,832,094.
●	Clinic-Level Adjusted EBITDA (before corporate operating and public company expenses) (see table included) was approximately $333,000 in Q2 2026 compared to approximately $164,000 in Q1 2026, and approximately $951,000 for the year ended December 31, 2025.
●	Net income of $0.9 million, compared to net loss of $(3.6) million. The current year period included approximately $2.5 million gain on remeasurement related to the Birmingham acquisition. The prior-year period included approximately $2.1 million of losses from discontinued operations related to NAYA Therapeutics.
●	Adjusted EBITDA (see table included) was $(1.0) million compared to $(0.6) million.
●	Cash was $3.7 million at June 30, 2026.
●	As of August 14, 2026, the Company had 2,506,969 shares of common stock outstanding.

Recent Highlights

●	Growth through both core pillars: Q2 2026 benefited from a full-quarter contribution from Indiana-based Family Beginnings, while first-half revenue also reflected organic growth initiatives at Wisconsin Fertility Institute and the Georgia clinic. The results continue to reinforce INVO Fertility’s two primary growth avenues, organic growth within the existing clinic base and disciplined acquisitions of established fertility practices.
●	Birmingham clinic now wholly owned: In June 2026, INVO acquired the remaining ownership interests associated with its Birmingham, Alabama fertility clinic, converting the operation from a joint venture into a wholly owned subsidiary and providing the Company with operational control and 100% participation in future economics.
●	Platform investments to support expansion: The Company continues to build capabilities across operations, human resources and finance to support a larger clinic network, improve execution and integrate future acquisitions. These investments are designed to drive greater scalability and improved consolidated Adjusted EBITDA as the platform grows.

●

Clinical research and innovation: Gretchen Collins, M.D., of INVO’s Wisconsin Fertility Institute, presented five poster abstracts at the 2026 Midwest Reproductive Symposium International evaluating ovarian and subendometrial platelet-rich plasma in patients facing difficult IVF and endometrial-development challenges. The presentations highlight the physician expertise and patient-centered innovation within INVO’s clinic platform.

●

Robust acquisition opportunity set: The Company continues to evaluate a robust pipeline of U.S.-based, established, and profitable fertility clinics that may benefit from becoming part of a larger fertility services platform with shared operational, financial, and administrative resources.

Clinic-Level Adjusted EBITDA

INVO Fertility believes the clinic-level view provides investors with an important perspective on the earnings capacity and underlying value of its fertility services platform.

Management is focused on growing this contribution through higher patient volumes, expanded services and improved operating execution, while also adding (via its acquisition efforts) established, profitable clinics that can increase scale and allow corporate operating expenses to be supported across a larger revenue and earnings base.

Clinic-Level Adjusted EBITDA

(Unaudited, $ in thousands; before corporate operating expenses)

	FY 2025				Q1 2026				Q2 2026
$	951			$	164			$	333

Clinic-Level Adjusted EBITDA is a non-GAAP measure. See Use of Non-GAAP Measures. See full table reconciliation.

Management Commentary

“The second quarter continued the progress we demonstrated in the first quarter and provided further validation of our strategy,” said Steve Shum, Chief Executive Officer of INVO Fertility. “Revenue increased 17% supported by the first full-quarter contribution from Family Beginnings and continued growth initiatives across our clinic network. Just as importantly, the clinic platform remained profitable on an Adjusted EBITDA basis before corporate operating and public company expenses, generating approximately $333,000 during the second quarter and $0.95 million during fiscal 2025. We believe these results demonstrate both the underlying earnings power of the clinics we have assembled and the value of building a larger platform around them.”

“We also continued to execute on the next phase of our plan. In addition to realizing a full quarter of contribution from Family Beginnings, we brought the Birmingham clinic fully into the INVO organization and expanded the shared services and resources we provide across operations, finance, billing, human resources, and administration. Our objective is to pair strong local clinical teams with the support, capabilities, and best practices needed to grow patient volumes, broaden services, improve execution and make each clinic more successful as part of the INVO family.”

“Looking ahead, we intend to drive organic growth across our existing clinic network, leverage our corporate infrastructure across a larger revenue base, and pursue disciplined acquisitions of established, profitable fertility practices. With a growing operating platform, demonstrated clinic-level Adjusted EBITDA generation, an improved financial position, and a robust pipeline of opportunities, we believe INVO is increasingly well positioned to build a scaled fertility services company and create meaningful long-term value,” Shum concluded.

Second Quarter Financial Discussion

Revenue for the second quarter of 2026 was approximately $2.2 million, compared to approximately $1.9 million for the second quarter of 2025. The increase of approximately $0.3 million, or 17%, was primarily attributable to the addition of Family Beginnings following the February 2026 acquisition. Clinic revenue increased 18% to approximately $2.2 million, compared to approximately $1.8 million for the second quarter of 2025.

Cost of services was approximately $1.4 million for the second quarter of 2026, compared to approximately $1.1 million for the second quarter of 2025. The increase was primarily attributable to the addition of Family Beginnings and one-time staffing costs at the Georgia clinic. Selling, general and administrative expenses decreased to approximately $1.9 million, compared to approximately $2.2 million for the second quarter of 2025, primarily reflecting lower professional services expenses.

The Company reported a loss from operations of approximately $(1.3) million for the second quarter of 2026, compared to a loss from operations of approximately $(3.0) million for the second quarter of 2025. Net income was approximately $0.9 million, compared to a net loss of approximately $(3.6) million for the second quarter of 2025. The Company recognized an approximate gain of $2.5 million on remeasurement related to the Birmingham acquisition in the second quarter of 2026. The Company reported no loss from discontinued operations during the second quarter of 2026, compared to approximately $(2.1) million of losses from discontinued operations during the second quarter of 2025 related to NAYA Therapeutics.

The Company ended the second quarter of 2026 with approximately $3.7 million in cash, compared to approximately $2.1 million at December 31, 2025.

Webcast

INVO Fertility will host a webcast to discuss its Q2 2026 financial results and provide a business update on Monday, August 17, 2026, at 11:00 a.m. Eastern time.

Date and Time: Monday, August 17, 2026, at 11:00 a.m. Eastern time.

Live Webcast: https://app.webinar.net/yDAl3O9e8k4

Replay: A webcast replay will be available at https://app.webinar.net/yDAl3O9e8k4.

Use of Non-GAAP Measure

Included in this press release are references to Adjusted EBITDA and Clinic-Level Adjusted EBITDA, which are non-GAAP financial measures. These measures are not intended to be substitutes for financial measures reported in accordance with U.S. generally accepted accounting principles. Management believes that, when considered together with the GAAP figures, these measures provide meaningful information regarding operating performance, the earnings contribution of the Company’s clinic platform and trends in the business.

Clinic-Level Adjusted EBITDA represents Adjusted EBITDA generated by the Company’s fertility clinic operations before corporate operating expenses, as calculated by management. This measure is intended to provide visibility into the performance and earnings capacity of the operating clinic platform separately from the costs associated with managing a public company and building a larger acquisition platform. Adjusted EBITDA and Clinic-Level Adjusted EBITDA may be calculated differently by INVO Fertility than by other companies that disclose measures with the same or similar terms.

About INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on US-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. For more information, please visit invofertility.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements regarding organic growth initiatives, acquisition opportunities, integration of acquired clinics, balance sheet improvements, liquidity, the growth of our clinic platform and our ability to achieve cash flow break even or profitability, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

INVO Fertility, Inc.

Steve Shum, CEO

978-878-9505

sshum@invofertility.com

Investor Contact

Lytham Partners, LLC

Robert Blum

602-889-9700

INVO@lythampartners.com

INVO FERTILITY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2026				2025				2026				2025
Revenue:
Clinic revenue		$	2,167,785			$	1,832,094			$	4,150,018			$	3,453,647
Product revenue			7,700				31,560				40,692				47,192
Total revenue			2,175,485				1,863,654				4,190,710				3,500,839
Operating expenses:
Cost of services			1,352,665				1,090,540				2,634,912				2,131,485
Cost of goods sold			60,147				3,063				65,299				7,047
Selling, general, and administrative			1,906,750				2,193,049				4,082,849				3,750,371
Impairment loss			-				1,397,353				-				1,397,353
Depreciation and amortization			145,573				169,737				288,271				404,199
Total operating expenses			3,465,135				4,853,742				7,071,331				7,690,455
Loss from operations			(1,289,650	)			(2,990,088	)			(2,880,621	)			(4,189,616	)
Other income (expense):
Gain (loss) from equity method investment			(7,154	)			(19,911	)			15,014				(4,815	)
Gain on remeasurement			2,452,032				-				2,452,032				-
Gain (loss) on change in fair value of warrant liability			-				1,660,160				(3,790,225	)			1,660,160
Loss on debt extinguishment			(172,621	)			(692,270	)			(172,621	)			(692,270	)
Gain on settlement			-				939,500				-				939,500
Interest income			139,514				-				139,514				-
Interest expense			(177,227	)			(440,596	)			(357,550	)			(748,435	)
Total other income (expense)			2,234,544				1,446,883				(1,713,836	)			1,154,140
Net income (loss) from continuing operations before income taxes			944,894				(1,543,205	)			(4,594,457	)			(3,035,476	)
Provision for income taxes			56,154				-				56,154
Net income (loss) from continuing operations			888,740				(1,543,205	)			(4,650,611	)			(3,035,476	)
Loss on disposition			-				(1,534,517	)			-				(1,534,517	)
Loss from discontinued operations			-				(541,247	)			-				(16,452,562	)
Net income (loss)		$	888,740			$	(3,618,969	)		$	(4,650,611	)		$	(21,022,555	)
Net income (loss) from continuing operations per common share:
Basic		$	0.42			$	(155.31	)		$	(2.48	)		$	(405.93	)
Diluted		$	0.35			$	(155.31	)		$	(2.48	)		$	(405.93	)
Net loss from discontinued operations per common share:
Basic		$	-			$	(208.91	)		$	-			$	(2,405.38	)
Diluted		$	-			$	(208.91	)		$	-			$	(2,405.38	)
Net income (loss) per common share:
Basic		$	0.42			$	(364.23	)		$	(2.48	)		$	(2,811.31	)
Diluted		$	0.35			$	(364.23	)		$	(2.48	)		$	(2,811.31	)
Weighted average number of common shares outstanding:
Basic			2,105,595				9,936				1,873,019				7,478
Diluted			2,592,025				9,936				1,873,019				7,478

Adjusted EBITDA
		For the Three Months Ended
		June 30,
		2026				2025
Net income (loss) from continuing operations		$	888,740			$	(1,543,205	)
Interest expense			177,227				440,596
Interest income			(139,514	)			-
Tax expense			56,154				-
Depreciation and amortization			145,573				169,737
Stock-based compensation			118,571				680,680
Non cash compensation for services			-				45,000
Gain on remeasurement			(2,452,032	)			-
Gain on change in fair value of warrant liability			-				(1,660,160	)
Loss from debt extinguishment			172,621				692,270
Gain on settlement of liability			-				(939,500	)
Impairment of intangible assets			-				1,397,353
NAYA divesture related costs			-				130,000
Adjusted EBITDA		$	(1,032,660	)		$	(587,229	)

Clinic-Level Adjusted EBITDA

Fertility Clinic Services Segment		2025				Q1 2026				Q2 2026
Revenue		$	6,721,057			$	1,982,233			$	2,167,785
Operating expenses			7,753,371				1,853,109				1,867,454
Segment profit			(1,032,314	)			129,124				300,331
Depreciation and amortization			585,897				34,821				32,695
Impairment loss			1,397,353				-				-
Fertility Clinic Services Segment EBITDA		$	950,936			$	163,945			$	333,026

2025 data derived from Note 15 - Segment Reporting in the Company’s 10-K

Q1 2026 data derived from Note 16 - Segment Reporting in the Company’s first quarter 10-Q

Q2 2026 data derived from Note 16 - Segment Reporting in the Company’s second quarter 10-Q

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 155.1 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB